Triple
T33292477
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | light chain amyloidosis |
E852351
|
entity |
| Predicate | instanceOf |
P0
|
FINISHED |
| Object | immunoglobulin light chain deposition disease |
C59625
|
CONCEPT FINISHED |
How this triple was built (1 step)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
CD
Concept disambiguation
gpt-5-mini-2025-08-07
Target class: immunoglobulin light chain deposition disease Context triple: [light chain amyloidosis, instanceOf, immunoglobulin light chain deposition disease]
-
A.
lymphoid neoplasm
A lymphoid neoplasm is a clonal proliferation of lymphoid cells (B cells, T cells, or NK cells) that forms a benign or malignant tumor arising in lymphoid tissues such as lymph nodes, bone marrow, or extranodal sites.
-
B.
lymphoma
Lymphoma is a type of cancer that originates in the lymphatic system, specifically from lymphocytes, a kind of white blood cell involved in immune responses.
-
C.
granulomatous disease
Granulomatous disease is a condition characterized by chronic inflammation in which the immune system forms organized clusters of macrophages (granulomas) in response to persistent infectious or noninfectious stimuli.
-
D.
amyloid-related imaging abnormality
Amyloid-related imaging abnormality (ARIA) is a radiologic finding, often seen on MRI in patients receiving anti-amyloid therapies, characterized by transient brain edema (ARIA-E) and/or microhemorrhages or superficial siderosis (ARIA-H) associated with cerebral amyloid deposition.
-
E.
Bruton tyrosine kinase inhibitor
A Bruton tyrosine kinase inhibitor is a targeted small-molecule drug that blocks BTK signaling in B cells to disrupt pathways critical for their activation, proliferation, and survival, primarily used in the treatment of certain B-cell malignancies and autoimmune diseases.
- F. None of above. chosen
Provenance (1 batch)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69f349660ff48190a4568803d0b89941 |
completed | April 30, 2026, 12:21 p.m. |
Created at: May 1, 2026, 1:33 a.m.